Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.

Literature DB >> 20044756

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.

Sandra Camelo-Piragua, Michael Jansen, Aniruddha Ganguly, J Chulmin Kim, David N Louis, Catherine L Nutt.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20044756 PMCID： PMC2864729 DOI： 10.1007/s00401-009-0632-y

Source DB: PubMed Journal: Acta Neuropathol ISSN： 0001-6322 Impact factor: 17.088

× No keyword cloud information.

12 in total

1. Monoclonal antibody specific for IDH1 R132H mutation.

Authors: David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling
Journal: Acta Neuropathol Date: 2009-10-02 Impact factor: 17.088

Review 2. The p53 gene and protein in human brain tumors.

Authors: D N Louis
Journal: J Neuropathol Exp Neurol Date: 1994-01 Impact factor: 3.685

3. Analysis of the IDH1 codon 132 mutation in brain tumors.

Authors: Jörg Balss; Jochen Meyer; Wolf Mueller; Andrey Korshunov; Christian Hartmann; Andreas von Deimling
Journal: Acta Neuropathol Date: 2008-11-05 Impact factor: 17.088

4. Immunocytochemical detection of p53 in human gliomas.

Authors: J M Bruner; H Saya; R P Moser
Journal: Mod Pathol Date: 1991-09 Impact factor: 7.842

5. An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy.

Authors: G A Lammie; A Beckett; R Courtney; F Scaravilli
Journal: Acta Neuropathol Date: 1994 Impact factor: 17.088

6. An integrated genomic analysis of human glioblastoma multiforme.

Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal: Science Date: 2008-09-04 Impact factor: 47.728

7. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors: Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal: Am J Pathol Date: 2009-02-26 Impact factor: 4.307

8. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors: Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal: Acta Neuropathol Date: 2009-06-25 Impact factor: 17.088

9. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors: Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal: Neuro Oncol Date: 2009-05-12 Impact factor: 12.300

10. IDH1 and IDH2 mutations in gliomas.

Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079

31 in total

1. Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.

Authors: Virginie Desestret; Pietro Ciccarino; François Ducray; Emmanuelle Crinière; Blandine Boisselier; Marianne Labussière; Marc Polivka; Ahmed Idbaih; Gentian Kaloshi; Andreas von Deimling; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Marc Sanson
Journal: J Neurooncol Date: 2011-04-24 Impact factor: 4.130

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.

1. Monoclonal antibody specific for IDH1 R132H mutation.

Review 2. The p53 gene and protein in human brain tumors.

3. Analysis of the IDH1 codon 132 mutation in brain tumors.

4. Immunocytochemical detection of p53 in human gliomas.

5. An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy.

6. An integrated genomic analysis of human glioblastoma multiforme.

7. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

8. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

9. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

10. IDH1 and IDH2 mutations in gliomas.

1. Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.

Review 2. The evolving molecular genetics of low-grade glioma.

Review 3. Update on molecular findings, management and outcome in low-grade gliomas.

Review 4. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Review 5. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

6. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.

7. Something old and something new about molecular diagnostics in gliomas.

8. How molecular testing can help (and hurt) in the workup of gliomas.

9. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

10. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.